External broker reports(aggregated public sources), CMB International

CMB International

External broker reports(aggregated public sources)

Incorporated in Hong Kong, supported by the mainland and targeting in global market, CMB International Capital Corporation Limited (“CMBI”) is an integrated financial institution providing comprehensive and professional services. As a wholly-owned subsidiary of China Merchants Bank ("CMB"), by leveraging on the Group’s synergy and coordination in domestic and overseas markets, as well as CMB’s strong resources and outstanding social reputation, CMBI and its subsidiaries have been actively implementing diversified business strategies and set up an overall layout of main business segments including Corporate Finance, Asset Management, Wealth Management, Global Markets and Structured Finance, etc. Adhering to the philosophy of “being clients oriented and increasing our own values by the way of creating value for clients”, CMBI endeavors to provide quality and integrated financial services to institutional, corporate and individual customers both domestic and overseas including Hong Kong IPO sponsorship and underwriting, share placement and rights issue for listed companies, financial advisors, bonds issuance services, asset management, direct investment, wealth management, equity sales and trading, etc.

Equity Bottom-Up

<div><div><div><div><ul><li>We moderately trim our 2022/23E earnings by 6-7% p.a as we now attempt to factor-in 1) a lower GPM (by average 0.8pp) due to higher non-infant milk formula contribution and 2) a 1.5pp higher selling expense.</li><li>Our forecast in general is at the low end/ slightly below management guidance, as we believe a low birth rate could compound with an intensifying competition to weigh on margins and drive up promotion expenses.</li><li>Despite this, Feihe’s sequential sales recovery sustains our BUY rating.</li></ul></div></div></div></div><p><em>Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.</em></p>

We moderately trim our 2022/23E earnings by 6-7% p.a as we now attempt to factor-in 1) a lower GPM (by average 0.8pp) due to higher non-infant milk formula contribution and 2) a 1.5pp higher selling expense.Our forecast in general is at the low end/ slightly below management guidance, as we believe a low birth rate could compound with an intensifying competition to weigh on margins and drive up promotion expenses.Despite this, Feihe’s sequential sales recovery sustains our BUY rating.Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

China Feihe (6186 HK) – Completion of channel restructuring continues to drive a steady 2H recovery

China

China Feihe specializes in the development, production, and sale of infant formula milk, other dairy products, and nutritional supplements. The company offers a range of products including infant milk formula, adult milk powder, liquid milk, and health care products. Founded in 1962, its headquarters are in Beijing, China.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

China Feihe (6186 HK) – Completion of channel restructuring continues to drive a steady 2H recovery

We moderately trim our 2022/23E earnings by 6-7% p.a as we now attempt to factor-in 1) a lower GPM (by average 0.8pp) due to higher non-infant milk...

CMB International